Stock Track | Tango Therapeutics Soars 5.10% Intraday on Better-Than-Expected Q4 Results and New Clinical Collaboration

Stock Track03-05

Tango Therapeutics Inc. (TNGX) saw its stock soar 5.10% during intraday trading on Thursday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and the announcement of a new clinical collaboration.

The clinical-stage biotechnology company reported a Q4 net loss of $0.29 per diluted share, narrowing from a $0.32 loss a year earlier and beating the FactSet consensus estimate of a $0.30 loss. The company also reported a strong cash position of $343.1 million as of December 31, 2025, which it expects to fund operations into 2028.

Adding to the positive sentiment, Tango announced a clinical trial collaboration and supply agreement with Erasca Inc. to evaluate Tango's PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015. The company also provided optimistic business updates, noting that its lead clinical program, vopimetostat, continues to demonstrate best-in-class potential and is on track to launch its first pivotal study in second-line pancreatic cancer this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182851853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182851853","market":"nz","top_or_hot":-1,"title":"Stock Track | Tango Therapeutics Soars 5.10% Intraday on Better-Than-Expected Q4 Results and New Clinical Collaboration","media":"Stock Track","content":"<p>Tango Therapeutics Inc. (TNGX) saw its stock soar 5.10% during intraday trading on Thursday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and the announcement of a new clinical collaboration.</p><p>The clinical-stage biotechnology company reported a Q4 net loss of $0.29 per diluted share, narrowing from a $0.32 loss a year earlier and beating the FactSet consensus estimate of a $0.30 loss. The company also reported a strong cash position of $343.1 million as of December 31, 2025, which it expects to fund operations into 2028.</p><p>Adding to the positive sentiment, Tango announced a clinical trial collaboration and supply agreement with Erasca Inc. to evaluate Tango's PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015. The company also provided optimistic business updates, noting that its lead clinical program, vopimetostat, continues to demonstrate best-in-class potential and is on track to launch its first pivotal study in second-line pancreatic cancer this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tango Therapeutics Soars 5.10% Intraday on Better-Than-Expected Q4 Results and New Clinical Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tango Therapeutics Soars 5.10% Intraday on Better-Than-Expected Q4 Results and New Clinical Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-05 22:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tango Therapeutics Inc. (TNGX) saw its stock soar 5.10% during intraday trading on Thursday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and the announcement of a new clinical collaboration.</p><p>The clinical-stage biotechnology company reported a Q4 net loss of $0.29 per diluted share, narrowing from a $0.32 loss a year earlier and beating the FactSet consensus estimate of a $0.30 loss. The company also reported a strong cash position of $343.1 million as of December 31, 2025, which it expects to fund operations into 2028.</p><p>Adding to the positive sentiment, Tango announced a clinical trial collaboration and supply agreement with Erasca Inc. to evaluate Tango's PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015. The company also provided optimistic business updates, noting that its lead clinical program, vopimetostat, continues to demonstrate best-in-class potential and is on track to launch its first pivotal study in second-line pancreatic cancer this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNGX","symbol_name":"Tango Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1182851853","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182851853","pubTimestamp":1772722559,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tango Therapeutics Inc. (TNGX) saw its stock soar 5.10% during intraday trading on Thursday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNGX":"Tango Therapeutics Inc."},"translate_title":"个股追踪|Tango Therapeutics盘中大涨5.10%，因Q4业绩好于预期和新的临床合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":1},"content_text":"Tango Therapeutics Inc. (TNGX) saw its stock soar 5.10% during intraday trading on Thursday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and the announcement of a new clinical collaboration.The clinical-stage biotechnology company reported a Q4 net loss of $0.29 per diluted share, narrowing from a $0.32 loss a year earlier and beating the FactSet consensus estimate of a $0.30 loss. The company also reported a strong cash position of $343.1 million as of December 31, 2025, which it expects to fund operations into 2028.Adding to the positive sentiment, Tango announced a clinical trial collaboration and supply agreement with Erasca Inc. to evaluate Tango's PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015. The company also provided optimistic business updates, noting that its lead clinical program, vopimetostat, continues to demonstrate best-in-class potential and is on track to launch its first pivotal study in second-line pancreatic cancer this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182851853","isCrawlerRequest":true}